Article citationsMore>>
Wang, L., Woods, K.W., Li, Q., Barr, K.J., McCroskey, R.W., Hannick, S.M., Gherke, L., Credo, R.B., Hui, Y.H., Marsh, K., Warner, R., Lee, J.Y., Zielinski-Mozng, N., Frost, D., Rosenberg, S.H. and Sham, H.L. (2002) Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure-Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation. Journal of Medicinal Chemistry, 45, 1697-1711.
https://doi.org/10.1021/jm010523x
has been cited by the following article:
-
TITLE:
Molecular Modeling and Synthesis of New Heterocyclic Compounds Containing Pyrazole as Anticancer Drugs
AUTHORS:
Fiby N. Takla, Abdelbasset A. Farahat, Magda A.-A. El-Sayed, Magda N. A. Nasr
KEYWORDS:
Tubulin, CA-4, Anticancer, Pyrazole, Molecular Modeling
JOURNAL NAME:
International Journal of Organic Chemistry,
Vol.7 No.4,
December
15,
2017
ABSTRACT: Several modifications in CA-4 were reported in
literature for the development of various tubulin inhibitors. In our study,
twenty-two newly synthesized heterocyclic derivatives of Combretastatin A-4
(CA-4) have been tested for their cytotoxic effect on four different types of
cells with malignant behavior using CA-4 as a positive control. Compounds 5b, 15 and 16 showed the foremost potent antiproliferative activities
as compared to CA-4 with IC50 starting from 6.9 to 13.7 μM. Molecular docking
was performed with the crystal structure of tubulin employing a potent tubulin
inhibitor CA-4 as a parent molecule. Molecular study advised that 5b, 15, 16 and 17 are promising tubulin inhibitors.
Related Articles:
-
Moiz A. Siddiqui, Amjad Khan, Mehreen Zaka
-
Wei Wang, Bing Zhao, Chao Xu, Wenpeng Wu
-
K. Harathi, D. Giribabu, C. Varadarajulu Naidu
-
Rifaat Hilal, M. F Shibl, Moteaa El-Deftar
-
Danica S. Perušković, Nikola R. Stevanović, Aleksandar Đ. Lolić, Milan R. Nikolić, Rada M. Baošić